ArticleScientific reports2021

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.

Marta Libura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.